Navigation Links
Brain stress system presents possible treatment
Date:2/26/2008

A brain circuit that underlies feelings of stress and anxiety shows promise as a new therapeutic target for alcoholism, according to new studies by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH).

In preclinical and clinical studies currently reported online in Science Express, NIAAA Clinical Director Markus Heilig, M.D., Ph.D., and colleagues from the NIH, Lilly Research Laboratories, and University College in London found that a brain molecule known as the neurokinin 1 receptor, or NK1R, appears to be a central actor in stress-related drinking.

The researchers first demonstrated that NK1R plays an integral role in alcohol consumption in animals. Mice that were genetically engineered to lack NK1 receptors consumed much less alcohol than did normal mice with fully functional NK1R. Subsequently, in a small clinical study, the researchers showed that an experimental compound designed to block NK1 receptors reduced alcohol craving and improved overall wellbeing among recently detoxified alcohol-dependent individuals who had high levels of anxiety. Using functional brain imaging, the researchers also showed that the exaggerated sensitivity to negative stimuli seen in alcoholics was dampened with the medication, while the lack of responses to pleasurable stimuli was restored.

This work exemplifies the NIHs unique capacity for speeding the translation of promising laboratory discoveries into potential new medical treatments, notes NIH Director Elias Zerhouni, M.D.

These findings advance our understanding of the link between stress and alcohol dependence and raise the prospect of a new class of medications for treating alcoholism, adds NIAAA Director Ting-Kai Li, M.D.

Relapse to uncontrolled drinking after periods of sobriety is a defining characteristic of alcoholism and is often triggered by stress.

The driving force behind dependent individuals alcohol use transitions from what we call reward craving to relief craving, explains Dr. Heilig. By the time people seek treatment for alcoholism, the pleasurable or rewarding effects of the drug are gone for most patients. Instead, alcohol-dependent individuals often feel low, anxious and are sensitive to stress, and they use alcohol to relieve these bad feelings.

Previous studies have shown that a brain chemical known as Substance P (SP) is released in response to stress, produces symptoms of anxiety, and binds preferentially to NK1R. SP and NK1R are highly expressed in brain areas involved in stress responses and drug reward. Studies have also shown that anxiety and stress responses can be reduced in both animals and humans by inactivating NK1R. Such studies suggest that interfering with NK1R function could possibly subvert any role it might play in stress-related alcohol consumption.

Dr. Heilig and his colleagues conclude that if further studies establish activation of the SP-NK1R system as a consistent feature of alcohol dependence, compounds that block NK1R may have considerable potential for treating alcoholism, and potentially other addictions.


'/>"/>

Contact: John Bowersox
301-443-2857
NIH/National Institute on Alcohol Abuse and Alcoholism
Source:Eurekalert

Related medicine news :

1. Youngest patient worldwide to have auditory implant in the brain stem
2. Fluoride May Damage the Brain, New Report Says
3. Autisms origins: Mothers antibody production may affect fetal brain
4. UC study: New devices less effective in thwarting brain aneurysm recurrence
5. New Stroke Treatments Reduce Brain Damage, Improve Recovery
6. Guidelines for evaluation of psychological side-effects of brain injury
7. Tumor-killing virus selectively targets diseased brain cells
8. Gene therapy trains immune system to destroy brain cancer cells and reverses behavioral deficits
9. Missing Chromosome Improves Response to Brain Tumor Treatment
10. Siblings of schizophrenia patients display subtle shape abnormalities in brain
11. Study suggests antibiotic may prevent dreaded brain fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Routine ... measurements are consistently correct. However, regular performance testing is often neglected because ... a solution: SmartCal™ . This innovative test substance offers a fast ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... Johnson & Weaver, LLP announces that a class ... Biomet Holdings, Inc. (NYSE: ZBH )  securities during ... (the "Class Period"). Zimmer Biomet provides musculoskeletal healthcare ... products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016 Sickle ... by rigid, sickle-shaped red blood cells that get stuck ... severe pain, stroke, organ failure, and complications leading to ... are born with SCD, and most of them lack ... fact, the only established long-term therapy for SCD, a ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: